# IHI Call Days | Call 12

INTERACT: Accurate Tissue Characterization with Deep-silicon Photon-Counting CT (PCCT) for Precision Cardiac and Oncology Diagnostics

Contact person name: Annamaria Csizmadia

Organisation: GE HealthCare

E-mail: annamaria.csizmadia@gehealthcare.com

innovationoffice@gehealthcare.com

Link to the IHI brokerage platform: IHI Call 12- Brokerage Event and Platform

- Proposal sharing tool
- Participant profile



# Clinical challenges in Conventional CT imaging.

### **Challenges**

- Limited accuracy in tissue characterization Traditional CT struggles to precisely characterize soft tissues, often requiring additional tests.
- Unnecessary repeat testing Initial scans may be inconclusive, leading to multiple follow-up procedures that increase cost and delay care.
- Overuse of invasive procedures Many patients undergo invasive diagnostics that could be avoided with more precise imaging.
- Complex and hard-to-use systems Advanced CT technologies are difficult to implement in everyday clinical settings due to complicated workflows.
- Slow diagnosis timelines Sequential testing and interpretation delays treatment decisions and impacts patient outcomes.
- Strain on healthcare resources High reliance on advanced imaging like MRI burdens healthcare systems, especially in less-equipped facilities.
- Poor patient communication Imaging reports are often too technical, making it hard for patients to understand their condition or participate in decisions.

### **Opportunities with Si-PCCT**

- Improved tissue clarity New Si detectors offer better spectral resolution, enabling more precise diagnosis in a single scan.
- Fewer motion-related issues Advanced motion correction reduces image distortion from cardiac and respiratory motion.
- High-quality imaging with lower radiation Efficient reconstruction algorithms allow clearer images with less exposure to radiation.
- Reduced need for extra tests More definitive initial scans can eliminate the need for additional imaging.
- **Fewer invasive procedures** Better anatomical detail helps avoid unnecessary interventions.
- Faster clinical decisions Al tools support quicker interpretation and help quide treatment earlier.

# Clinical Innovation - solution

Silicon-based PCCT offers ultra-high spatial resolution and spectral fidelity, enabling:

### **Cardiac Imaging Advancements**

- Enables detailed visualization of coronary plaques, including non-calcified and lipid-rich components.
- **Identifies high-risk features** such as large lipid-rich necrotic cores with thin fibrous caps, which are critical for assessing vulnerability to rupture.
- Provides quantitative plaque burden and composition analysis for risk stratification and monitoring of therapeutic response.
- Offers accurate quantification of coronary stenosis and detailed plaque characterization using spectral data, including visualization of non-calcified and lipid-rich plaques.
- Goes beyond anatomical assessment by facilitating functional evaluation through flow measurement and myocardial perfusion imaging, enabling assessment of ischemia and myocardial viability.
- Supports 4D imaging capabilities for dynamic evaluation of cardiac wall motion, ejection fraction, and valvular function, enhancing diagnostic accuracy

# **Oncology Imaging Advancements**

- Enhanced visualization of soft tissue lesions, including small or ambiguous nodules in the lungs, liver, pancreas, and lymph nodes.
- Improved differentiation between benign and malignant tissue through precise material decomposition and contrast enhancement.
- Quantitative assessment of tumour composition and vascularity, supporting early detection, staging, and monitoring of treatment response.
- Reduced reliance on follow-up MRI or PET scans, streamlining diagnostic workflows and improving access in resource-limited settings.



# Main focuses

- Deliver more definitive cardiology and oncology insights beyond that of today's clinically available technology by developing and validating advanced deep silicon PCCT acquisition, reconstruction, and Al-driven interpretation software. The goal is for the innovations to reduce follow-up tests.
  - Cardiology will focus on functional and anatomical assessment of Coronary Artery Disease
  - Oncology will span from diagnostic to Radiation Therapy planning
- Design and test workflow solutions that democratize access to advanced imaging, including deviceless ECG gating and automated metrics for non-elite healthcare centers.
- Create patient-friendly reports that support shared decision-making and improve health literacy.
- Make PCCT available to more communities by reducing the cost of manufacturing and servicing of PCCT through innovation.

# Cardiac-dedicated acquisition and reconstruction innovation and interpretation software: capture the fast-moving heart anatomy at high detail improve the ease of cardiac PCCT acquisition for

- non-elite centers (e.g., deviceless ECG gating)
- take advantage of the intrinsic spatial and spectral resolution of the system to visualize functional and anatomical detail of Coronary Artery Disease (CAD)
- Simple to use plaque characterization and myocardial perfusion with disease correlation (Albased) and patient-friendly report structure
- Oncology acquisition, reconstruction, and interpretation software:

Development

echnology

- High spectral fidelity imaging with simple workflowtaking advantage of spectral separation of deep Si PCCT for advanced lesion/tumor differentiation and radiation oncology planning
- Develop tools for automated characterization of lesions in CT with simple workflow to increase accessibility to non-academic imaging facilities with patient-friendly report structure
- Rad Onc expand dSi PCCT benefits to RT Simulation and understand how always on spectral imaging can improve OAR identification, removal of artifacts, improve target definition, etc.
- Reduce cost of manufacturing and servicing of PCCT

# Impact & Outcomes











# For patients

### For clinicians

# For radiology institutions

# For healthcare systems

### For EU

Faster Access to Diagnosis and Treatment: Shortened diagnostic timelines lead to earlier interventions

Reduced Diagnostic Burden: Fewer procedures and lower radiation exposure enhance safety and comfort.

**Empowered Engagement**: Clearer and quicker results help patients participate more actively in their care decisions.

Reduction in unnecessary follow-up procedures, lowering patient burden.

**Better Prognosis**: Early and accurate diagnosis improves the likelihood of successful treatment and recovery.

Enhanced Diagnostic Accuracy Context-rich imaging reduces uncertainty and improves tissue characterization.

Improved Risk Stratification Quantitative tissue data supports personalized treatment planning.

Support for Personalized Medicine High-resolution imaging and Al insights enable individualized care in oncology and cardiology.

Faster Clinical Decisions
Deep learning—driven triage systems support earlier, better-informed decisions.

Longitudinal Monitoring
Enables tracking of disease
progression and therapeutic response,
enhancing continuity of care.

Streamlined Workflows
Minimizes repeat scans and
inconclusive results, boosting
operational efficiency.

**Safer Imaging Practices** 

Minimizes radiation exposure for patient & staff.

Reduced Follow-Up Procedures
Lowers reliance on invasive or costly
tests

**Operational Efficiency** 

Improves throughput and reduces scan redundancy, lowering costs and increasing capacity.

Technological Leadership

Advances institutions in precision imaging with Al-integrated PCCT.

**Scalable Infrastructure** 

Supports future expansion and integration of advanced diagnostic models.

Enhanced Research Capabilities Enables studies in tissue characterization, AI diagnostics, and imaging biomarkers. **Expanded Access** 

Simplified workflows and automation enable advanced diagnostics in resource-limited settings.

**Cost Reduction** 

Cuts hospital expenses by improving first-scan accuracy and reducing unnecessary procedures.

**Affordable Technology** 

Advances in PCCT design help reduce the cost of high-performance CT scanners.

**Improved Care Coordination** 

Rich imaging data supports multidisciplinary collaboration and integrated care pathways.

**Strategic Alignment** 

Supports hospital goals in digital transformation, quality improvement, and value-based care.

**Clinical Readiness** 

Strong evidence base supports integration into routine care for cancer and cardiovascular diseases.

**Public Health Impact** 

Early, accurate diagnosis improves outcomes and reduces long-term healthcare burden.

Sustainable Care Minimizes unnecessary procedures and hospital stays, aligning with cost-effective healthcare goals.

Innovation Leadership
Reinforces Europe's role in Aldriven medical imaging and precision diagnostics.

Policy Alignment
Supports EU strategies in
digital health, personalized
medicine

# Expertise and resources

### • We have:

Diagnostic: Medical Devices
 Digital: Al-tools, Al boosted healthcare application

### We are looking for:

- Clinical institutions with established expertise in diagnostic oncology and in cardiac imaging.
- Pharmaceutical partners developing lipid-lowering therapies to support longitudinal studies on plaque evolution and treatment efficacy.
- Medical technology companies specializing in lung biopsy systems and minimally invasive diagnostics to support tissue confirmation and downstream care pathways.
- Computing and data infrastructure expertise in HPC, cloud imaging, and AI-driven data processing to handle and analyze large-scale PCCT datasets for longitudinal and diagnostic applications
- Patient organizations

